Maxim Group Maintains Buy on BioHarvest Sciences, Lowers Price Target to $5
Maxim Group analyst Anthony Vendetti maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $12 to $5.
Read original at benzingaStocks · News reference
BioHarvest Sciences Enters Agreement For A Rare, Endangered Fragrance Plant Cell Culture With A UAE-Based Customer; Sees $20M-$30M In 2027-28 Sales
This particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 10:09 AM
- Checked
- Aug 11, 2026, 10:09 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8
Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.
Read original at benzingaConference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
Read original at benzingaBioHarvest Sciences shares are trading higher after the company reported Q2 financial results. The company revised its FY26 CDMO revenue guidance.
Read original at benzinga